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Objectives: Surveillance programs are recommended to both families at high risk
(Amsterdam-positive families with known- and unknown mutation) and moderate risk
(families not fulfilling all Amsterdam criteria) of colorectal cancer (CRC).
Cost-effectiveness has so far only been estimated for the group at high risk. The aim of
the present study is to determine cost-effectiveness of surveillance programs where
families at both high and moderate risk of HNPCC participate.
Methods: A decision analytic model (Markov model) is developed to assess surveillance
programs where families at high and moderate risk of HNPCC are offered surveillance
from age 25 and age 45, respectively. The model includes costs for all families referred to
genetic counseling, including genetic risk assessment, mutation analysis, and
surveillance in relevant families with or without known mutation, plus the costs related to
any surgical treatment. The risk of metachronous CRC is also modeled.
Results: Incremental costs per life year gained are estimated to be €980 when families at
both high and moderate risk of HNPCC undergo surveillance (€508 for high risk and
€1 600 for moderate risk) and €1 947 when the moderate risk group is evaluated
genetically but not offered surveillance. Sensitivity analysis showed these findings to be
robust, although cost-effectiveness can be improved in cases of more conservative
referrals to genetic counseling.
Conclusions: The result for high risk families confirms the findings in similar studies.
Somewhat surprisingly, cost-effectiveness improves when surveillance of the moderate
risk groups are included in the decision model.
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Hereditary non-polyposis colorectal cancer (HNPCC) is
an autosomal dominantly inherited disease. Surveillance
by colonoscopy with removal of adenomas and colec-
tomy/proctocolectomy in case of colorectal cancer (CRC)
effectively reduces cancer risk and mortality (11;12). The
Danish recommendations for colorectal surveillance in
HNPCC families are colonoscopy and removal of adenomas
every second year from the age of 25 in high risk families and
every second year from the age of 45 in most of the moderate
risk families, for example late onset. More than one third of
all families referred to counseling in Denmark have a mod-
erate risk of CRC. There are no systematic population-based
CRC screening programs in Denmark.
Cost-effectiveness studies of HNPCC have tended to fo-
cus upon detection of mutation carriers (5;6;13;16–18). The
outcomes in these studies have largely been the cost per de-
tected mutation carrier or the incremental cost-effectiveness
of alternative strategies to detect mutation carriers. Kievit
et al. (2005) estimate cost-effectiveness of a new strategy
(microsatellite instability analysis) for detecting HNPCC
among the population of colorectal cancer patients compared
with current practice. The only study that evaluates the cost-
effectiveness of HNPCC surveillance versus no surveillance
finds the surveillance strategy dominant (i.e., both lower
costs and better effect) (23). Both Kievit et al. (2005) and
Vasen et al. (1998) evaluate cost-effectiveness of high risk
families only. On the one hand, this tends to overestimate
cost-effectiveness of surveillance programs because it fails
to include surveillance costs connected to families at moder-
ate risk. On the other hand, failing to take advantage of the
effectiveness of surveillance for families with moderate risk
of CRC could result in cost-effectiveness being underesti-
mated.
The present study evaluates the cost-effectiveness of
HNPCC surveillance versus no surveillance with the Dan-
ish surveillance program as base case. The model allows for
assessing the isolated cost-effectiveness of high and mod-
erate risk programs as well as various scenarios for genetic
testing and genetic counseling. The research question posed
is whether surveillance of both high risk and moderate risk
families is cost-effective compared with a no surveillance
strategy.
METHODS
Study Design/Interventions
We developed a Markov model to evaluate cost-effectiveness
(Figure 1). For simplicity, we assume that all individuals
enter at age 25 (even though surveillance is first offered to
moderate risk families at age 45). We use a Markov cycle
length of 1 year. Individuals enter the model when referred for
genetic counseling and either enter the different surveillance
programs or are excluded from this if they have no increased
risk of CRC.
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Figure 1. Simplified Markov state diagram of the surveillance
and the no-surveillance strategies.
The two-headed arrows from the risk stages to the CRC
stage indicate the risk of metachronous colorectal cancer. The
no-surveillance strategy omits the counseling and mutation
analysis stages and merges the two risk stages.
The surveillance program is modeled in three steps:
(i) genetic counseling and mutation testing, (ii) colonoscopic
surveillance of individuals at increased risk, (iii) colectomy
with ileorectal anastomosis or proctocolectomy at onset of
CRC (and chemotherapy at onset for late stage CRC [Dukes
C and D]). The costs of these steps are accumulated in the
surveillance strategy. In the no-surveillance strategy, only
costs of segmentary colon resection (and chemotherapy at
late stage CRC) are accumulated. After genetic counsel-
ing and testing, the individuals are categorized into one of
four risk-groups: (i) high risk with identified mutation, (ii)
high risk with unidentified mutation, (iii) moderate risk, or
(iv) low risk.
High risk is defined as families that fulfill the Amster-
dam I or II criteria with or without an identified mutation. The
Amsterdam I criteria are: (i) at least three family members
with CRC, one of them being a first-degree relative, (ii) at
least two successive generations are affected, (iii) one with
CRC before age 50, and (iv) familial adenomatous poly-
posis is excluded. In Amsterdam II criteria, CRC may be
exchanged with endometrial, small bowel, or upper urinary
tract cancer. Moderate risk refers to families suspected of
HNPCC although not fulfilling the criteria, for example, late-
onset HNPCC where none of the affected family members
are under 50 years of age. Low risk refers to sporadic CRC.
Mutation screening was performed by sequencing the
exons and the exon–intron junctions of the MLH1 and MSH2
genes.
Surveillance is offered for both high risk groups and for
the moderate risk group, but not for the low risk group. Cost-
effectiveness is defined as the incremental costs per life year
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Table 1. Data for Baseline Simulation
Base case Source of data
Colonoscopy €349 (22)
Colectomy €9,435 (22)
Segmentary resection €9,435 (22)
Chemotherapy (Dukes C and D) €12,320 (22)
Genetic counseling €1,344 a
Mutation analysis €1,165/family b
Presymptomatic tests €269/individual b
Counseling and detection rate for mutation analyses
Average % of low risk families “erroneously” referred to counseling 31% (2;3)
Average % of high risk families of families referred to counseling 33% (2;3)
Average % of moderate risk families of families referred to counseling 36% (2;3)
Detection rate (% of screenings where the mutation is found) 22% b
Epidemiological data and mortality rates
Age-dependent CRC incidence: sporadic c (21)
Age-dependent CRC incidence: high risk, unknown mutation c (11)
Age-dependent CRC incidence: high risk mutation carriers c (1;11;24)
Age-dependent CRC incidence: moderate risk c a
Reduction in CRC risk due to surveillance 62% (12)
Risk of metachronous CRC: sporadic CRC .05 over 10 yr (15)
Risk of metachronous CRC: high risk, under surveillance .12 over 12 yr (19)
Risk of metachronous CRC: high risk, no surveillance d (2)
5-year survival rate: sporadic CRC 0.43 (21)
5-year survival rate: high risk under surveillance 1.00 (12)
5-year survival rate: high risk without surveillance .54 (12)
Mortality rate, all other causes c (7)
Note. All risk parameters are transformed to annual probabilities before used in the simulation model.
a Expert opinion.
b Average of three Danish centers.
c Values vary on the basis of patient’s age.
d Values vary on the basis of years gone since first CRC.
CRC, colorectal cancer.
gained for an average individual of the population referred to
genetic counseling. The decision analysis program Treeage
Pro (TreeAge Software, Inc., Williamstown, MA) is used to
evaluate the model.
Data
Costs for colonoscopy, colectomy with ileorectal anasto-
mosis, proctocolectomy, segmentary colon resection, and
chemotherapy are based on the Danish Diagnosis Related
Group rates from 2004 (22), whereas costs for genetic
counseling and mutation testing is based on expert opin-
ion and calculations from the screening centers, respectively
(Table 1). All cost parameters are converted from Danish
Kroner (DKK) to Euro (€) using an average exchange rate
for 2004 (1€= 7.44 DKK). Genetic counseling is assessed
at a cost of €1,344 per family (Table 1).
Since 1991, The national Danish HNPCC Register has
registered epidemiological and molecular–genetic informa-
tion on all Danish HNPCC families and suspected HNPCC
families in a PARADOX database system and a correspond-
ing pedigree program. The Register identifies HNPCC fam-
ilies and recommended screening programs, as do the other
genetic departments in Denmark, and all the data are col-
lected in the database, including the results of screening.
The annual number of Danish families referred to genetic
counseling averaged around 110 families in the period 1999–
2001 inclusive. After genetic risk assessment, 31 percent of
the families were defined as low risk, 33 percent were defined
as having a moderate risk, and the remaining 36 percent were
considered high risk families. The mutation analysis resulted
in identification of a mutation in 22 percent of the high risk
families. In families with identified mutation, the mutation
carriers (50 percent) belong to the high risk with identified
mutation, and 50 percent did not carry the mutation and were
consequently in the low risk group.
Epidemiologic Data and Mortality Rates
Incidence of colorectal cancer is modeled in 10-year age
intervals based on Ja¨rvinen et al. (1995) (11). The cancer
incidence for the moderate risk group is not known but is
assumed to be three times the cancer incidence of the low risk
group in each age interval. The lifetime risks of colorectal
cancer are 3.3 percent, 10.8 percent, 46 percent, and 80–
90 percent for the low risk, moderate risk, high risk with
unknown mutation, and high risk with identified mutation,
respectively (11;21). The stage distribution of CRC under
surveillance (77 percent detected at an early stage—Dukes
A or B) and without surveillance (48 percent detected at an
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early stage—Dukes A or B) is modeled using Danish data
(4).
Rodriguez-Bigas et al. (1997) estimate of the risk of
rectal cancer after colectomy is used to model the risk of
metachronous cancer after colectomy (19). Estimates from
the Danish HNPCC registry are used to model the risk of
metachronous colorectal cancer after segmentary colon re-
section for the high risk group under surveillance (2). Es-
timates of metachronous colorectal cancer for the low risk
group are taken from Myrhøj et al. (15). It is assumed that the
moderate risk group has the same risk of metachronous col-
orectal cancer as the low risk group. Mortality rates are taken
from Ja¨rvinen et al. (2000) (12), whereas the risk of death
of other causes is estimated from mortality and population
statistics from Statistics Denmark (7). We use the estimate by
Ja¨rvinen et al. (2000) of a 62 percent reduction in incidence
as a result of surveillance for the high risk as well as for the
moderate risk group (12).
Sensitivity Analysis and Discounting
The available data provide little information about parame-
ter variation and uncertainty. It is increasingly being recom-
mended that sensitivity analysis is performed using stochastic
modeling and cost-effectiveness acceptability curves. How-
ever because of the limited information on parameter uncer-
tainty and because we are particularly interested in changes
in specific very uncertain parameters (as, e.g., the risk of
CRC for the moderate risk group), we have chosen to use
traditional univariate sensitivity analysis.
It is recommended that costs and life years be discounted
at 3 percent and to perform sensitivity analysis at 0 percent
and 5 percent discounting (20). Because cost is expected up
front and gains in life years occur in the future, discounting
heavily devaluates the cost-effectiveness of prophylactic in-
terventions (9). To obtain the most conservative estimate of
cost-effectiveness, we use 5 percent discounting in the base
case simulations. Sensitivity analysis is done to assess the
effect of parameter uncertainty in cost estimates, cancer inci-
dence and effectiveness of surveillance. Finally simulations
are performed to assess various scenarios for genetic testing
and genetic counseling.
RESULTS
Three sets of simulation results are provided: (i) price per
gained life year under base case assumptions, (ii) price per
gained life year under variation in pivotal base case assump-
tions (sensitivity analysis), and (iii) price per gained life
year under alternative surveillance program setups (scenario
analysis).
Base Case Results
Simulation with base case assumptions results in incremental
cost per life year gained on €249, €588 and €980 with 0
Table 2. Base Case Results
Incremental cost
Difference Difference per gained life
in life years in costs (€) years (€)
0% discount rate 4.07 1,012 249
3% discount rate 1.08 635 588
5% discount rate .51 500 980
High risk 2.01 1,021 508
Moderate risk .21 336 1,600
percent, 3 percent, and 5 percent discounting, respectively
(Table 2). Disaggregated to high and moderate risk groups,
the incremental costs per life year are estimated to€508 and
€1,600, respectively (at 5 percent discounting).
Sensitivity Analysis
Sensitivity analysis is performed for parameters based on
expert opinion, on costs related to surveillance (colonoscopy,
counseling, genetic testing), and on the reduction in CRC
incidence due to surveillance. The impact of changes in other
parameters is covered in the scenario analysis.
Colonoscopy costs have the largest influence on the re-
sults. If costs of colonoscopy were reduced with 50 percent,
then surveillance becomes the dominant strategy, that is,
surveillance is both cheaper and results in more life years
than a case without surveillance. Variation in costs on ge-
netic counseling and testing has less influence on the results
(Table 3).
The risk of colorectal cancer for the moderate risk group
is in base case assumed to be three times that of sporadic
CRC incidence. This finding turns out to be a very important
parameter. Sensitivity analysis reveals that cost-effectiveness
has an inflection point in connection to this parameter: both
higher (five times sporadic CRC) and lower incidence (two
Table 3. Sensitivity Analysis
Incremental
cost per gained
Base case Range life years (€)
Surveillance costs €349 [−50%;+50%] b 2,365
(colonoscopy)
Reduction in CRC 62% [25%;100%] 2,262 162
incidence due to
surveillance
Lifetime risk of 10.8 [7.2;18.0] 2,189 2,233
CRC for the
group at moderate
risk of HNPCCa
a The risk of CRC is assumed to be three times that of sporadic CRC in
base case, and the sensitivity range is two and five times that of sporadic.
Age-dependent risk is used in the simulation (see Table 1).
b The surveillance strategy dominates in the sense that it is both cheaper
and results in more life years.
CRC, colorectal cancer; HNPCC, hereditary non-polyposis colorectal
cancer.
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Table 4. Scenario Analysis
Incremental
cost per
Difference Difference gained life
in life years in costs (€) years (€)
Improve quality of 1.09 659 605
referrals to counseling
(low risk families
in counseling reduced
from 31% to 10%)
No surveillance of .17 331 1,947
moderate risk families
Improve detection .46 390 848
rate of mutation
analysis from
22% to 50%
No mutation analysis .50 473 946
times sporadic CRC) increases the incremental costs per life
year gained (€2,189 and €2,283 compared with €980).
Ja¨rvinen’s result of a 62 percent reduction in CRC risk
due to surveillance is used in base case. If this parameter were
reduced to 25 percent, then cost-effectiveness would fall by
130 percent (€2,262 compared with€980). If it increases to
100 percent, cost-effectiveness would increase by 84 percent
(€162 compared with €980).
Scenario Analysis
If surveillance were not offered to families at moderate risk
then the incremental costs for a gained life year is esti-
mated at €1,947. Cost-effectiveness would fall by around
40 percent (€605 compared with €980) if the number of
low risk families referred to counseling could be reduced
from 31 percent to 10 percent (Table 4). Increasing the detec-
tion rate of mutation analysis from the current 22 percent to
50 percent can improve cost-effectiveness by almost 15 per-
cent (€848 compared with €980). Omitting mutation anal-
ysis hardly affects the incremental cost per gained life year
(€946 compared with €980).
DISCUSSION
The strength of the present study is the use of data from
the Danish HNPCC database to build a simulation model
that explicitly models the consequence on cost-effectiveness
of: (i) no criteria for referral to genetic counseling, which
means that also low risk families would be referred; (ii) fam-
ilies with unknown mutation referred to surveillance; and
(iii) surveillance strategies for families at moderate risk of
CRC. The focus is on cost-effectiveness of surveillance
versus no surveillance, while most studies analyze cost-
effectives when comparing various screening strategies.
The estimated cost per gained life year when surveil-
lance of the moderate risk group was omitted was €1,947.
Of interest, including the moderate risk group in a surveil-
lance program suggested a huge reduction on the cost per
gained life year; €980 vs. €1,947. This finding is probably
because the costs of counseling of the moderate risk group
had already been effected, but failing to pursue the potential
gain in life years from colonoscopic surveillance would result
in poor cost-effectiveness. Sensitivity analysis revealed an-
other interesting result—namely that cost-effectiveness has
an inflection point in connection to the risk of CRC for the
moderate risk group. At first this might seem somewhat odd,
but a plausible explanation could be that, if the risk of CRC
is very low, then the benefits of surveillance are reduced
and cost-effectiveness falls. If on the other hand the risk is
high and tends toward that of the high risk group, then the
surveillance strategy starting at age 45 is too late to take
full advantage of the surveillance benefits, which then re-
duces cost-effectiveness. It should be noticed however that
even though cost-effectiveness is reduced with changes in
the risk parameter of the moderate risk group the change is
only marginal and does not alter the conclusion about cost-
effectiveness.
Even with the most conservative assumptions, our re-
sults show that the price for a gained life year never exceeds
€2,500. Compared with other healthcare interventions, this
finding makes HNPCC surveillance extremely cost-effective.
Devlin and Parkin (2004) evaluated the correlation between
interventions accepted by the British National Institute for
Clinical Excellence and cost-effectiveness rates. Of thirty-
three accepted interventions, only three had incremental cost-
effectiveness rates less than €2,500 (smoking cessation and
nicotine replacement, use of cytology in cervical cancer, and
topecetan treatment of ovarian carcinoma) (8).
Our findings of cost-effectiveness of the surveillance
program were less favorable than those of Vasen et al. (23)
but were in the same range as Kievit et al. (13). Vasen et al.
found that a similar surveillance strategy dominated the no
surveillance strategy (23), but this study only modeled mu-
tation carriers. By omitting the costs of genetic counseling
and risk assessment for hereditary CRC (HNPCC and moder-
ate risk families) and the costs of surveillance for individuals
with unknown mutation status, the cost estimates tended to be
too low. Furthermore, the estimated cost-effectiveness tends
to be too favorable because the study failed to discount life
years. Vasen et al. found an undiscounted gain in life years of
7 years for mutation carriers. The estimated gain in life years
for the high risk group in our study was estimated to 2 years
at 5 percent discounting (Table 2), which amount to 9 years
when life years were left undiscounted (not reported). Our
estimated gain in life years was thus, compared with Vasen’s
result, more favorable probably because our model included
the gained life years due to a reduction in metachronous
cancer, not directly modeled in Vasen’s study. In compari-
son, Kievit et al. (2005) estimated the gain in life years to
2.5 years under 4 percent discounting, almost identical to the
2 years found here with 5 percent discounting.
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The results in this study did not consider the effect of
possible improvements in detection of mutation carriers by
using analysis of microsatellite instability and/or immuno-
histochemistry. Recent studies analyzed the effectiveness of
these methods in various settings.
Kievit et al. evaluated the cost-effectiveness of using mi-
crosatellite instability analysis of selected families compared
with current practice without microsatellite instability anal-
ysis: 2.2 times more mutation carriers were detected when
using microsatellite instability analysis and an incremental
cost per life year gained on €2,184 compared with current
practice. In a population of 1,066 patients with newly diag-
nosed CRC, Hampel et al. (2005) found that no great loss
in sensitivity would occur if microsatellite instability anal-
ysis was replaced by immunohistochemical analysis. They
also found that identification of HNPCC families improved
by using these methods on all CRC compared with using
Amsterdam or Bethesda criteria (10;14). Pigatto et al. (2004)
analyzed 138 families referred to genetic service and found
that the strategy in achieving the highest sensitivity for the
lowest cost in identification of germline mutation in MLH1
and MSH2 was to use sensitive clinical criteria followed
by immunohistochemistry and, if this was normal, then mi-
crosatellite analysis (16). The results of these three stud-
ies indicate that cost-effectiveness of surveillance versus no
surveillance could be even more favorable than estimated in
the present study if microsatellite instability analysis and/or
immunohistochemical analysis were introduced before car-
rying out expensive mutation analysis.
POLICY IMPLICATIONS
The results of the present study show that cost-effectiveness
of surveillance programs for HNPCC families tends to be
underestimated in cases where the decision model does not
consider surveillance for families at moderate risk of CRC.
More restrictive criteria for referrals to genetic counseling
and improvements in the detection rate of mutation analysis
have a potential to improve cost-effectiveness even further.
More effective mutation screening has already been imple-
mented in the form of including the MSH6 gene (and in
rare cases the PMS2 gene also) and deletion analysis of the
MLH1, MSH2, and MSH6 genes. This will strengthen the
results of this cost-effectiveness analysis even more. The pol-
icy implications of the results is that surveillance ought to be
offered to high as well as moderate risk groups.
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